Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

CA29842P1053
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00Z83VR49
EPRX
Eupraxia Pharmaceuticals Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Eupraxia Pharmaceuticals Inc.
ISIN
CA29842P1053
TICKER
EPRX
MIC
XTSX
REUTERS
EPRX.TO
BLOOMBERG
EPRX CN
Fri, 19.06.2026       Eupraxia Pharmaceuticals
CA29842P1053

VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleas...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.05.2026       Eupraxia Pharmaceuticals
CA29842P1053

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       Eupraxia Pharmaceuticals
CA29842P1053

VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today annou...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Eupraxia Pharmaceuticals
CA29842P1053

VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today ann...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Eupraxia Pharmaceuticals
CA29842P1053

VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today ann...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.03.2026       Eupraxia Pharmaceuticals
CA29842P1053

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.02.2026       Eupraxia Pharmaceuticals
CA29842P1053

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Eupraxia Pharmaceuticals
CA29842P1053

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.01.2026       Eupraxia Pharmaceuticals
CA29842P1053

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improve...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.11.2025       Eupraxia Pharmaceuticals
CA29842P1053

Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE)...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 04.11.2025       Eupraxia Pharmaceuticals
CA29842P1053

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 29.09.2025       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, British Columbia, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, today provided an opera...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.09.2025       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today anno...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.08.2025       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today annou...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.07.2025       Eupraxia Pharmaceuticals
CA29842P1053

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.07.2025       Eupraxia Pharmaceuticals
CA29842P1053

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.06.2025       Eupraxia Pharmaceuticals
CA29842P1053

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Eupraxia Pharmaceuticals
CA29842P1053

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE)...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 06.05.2025       Eupraxia Pharmaceuticals
CA29842P1053

Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE)...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 24.04.2025       Eupraxia Pharmaceuticals
CA29842P1053

Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) will present at the upcoming investor and scientific conferences in April and May....
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.03.2025       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the f...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.03.2025       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, March 20, 2025 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth q...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.02.2025       Eupraxia Pharmaceuticals
CA29842P1053

Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increaseCohort 6 showed the greatest symptom relief scores ("SDI") of all cohorts to date at 12 weeksCohort 6 had the greatest magnitude and percentage change in tissue health scores ("EoEHSS") of any cohort to date at 12 weeksCohort 6 sa...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.02.2025       Eupraxia Pharmaceuticals
CA29842P1053

Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increaseCohort 6 showed the greatest symptom relief scores ("SDI") of all cohorts to date at 12 weeksCohort 6 had the greatest magnitude and percentage change in tissue health scores ("EoEHSS") of any cohort to date at 12 weeksCohort 6 sa...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.02.2025       Eupraxia Pharmaceuticals
CA29842P1053

Das Instrument X43 CA29842P1053 EUPRAXIA PHARMA. INC EQUITY hat seinen ersten Handelstag am 20.02.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N The instrument X43 CA29842P1053 EUPRAXIA PHARMA. INC EQUITY has its first trading date on 20.02.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.02.2025       Eupraxia Pharmaceuticals
CA29842P1053

-  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC, Feb. 18, 2025 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effect...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.02.2025       Eupraxia Pharmaceuticals
CA29842P1053

-  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC, Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer,...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.11.2024       Eupraxia Pharmaceuticals
CA29842P1053

DiffuSphere™ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues, enhancing efficacy while minimizing systemic drug levels to optimize safetyIn clinical trials, a single administration of DiffuSphere™ successfully delivered fluticasone propionate for at least six months in patients with eosinophilic...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.11.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company will be prese...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.11.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Nov. 14, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting a...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.11.2024       Eupraxia Pharmaceuticals
CA29842P1053

EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalenceRegistration for the webinar now open to the public by visiting EPRXNOV1524.TribePublic.comVICTORIA, BC, Nov. 13, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc....
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.11.2024       Eupraxia Pharmaceuticals
CA29842P1053

EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalenceRegistration for the webinar now open to the public by visiting EPRXNOV1524.TribePublic.comVICTORIA, BC, Nov. 13, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupra...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.11.2024       Eupraxia Pharmaceuticals
CA29842P1053

One of three patients in Cohort 5 achieved complete histological remission at 12 weeks.Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks.At 24 weeks, the fourth cohort experienced the largest average reduction in SDI...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.11.2024       Eupraxia Pharmaceuticals
CA29842P1053

One of three patients in Cohort 5 achieved complete histological remission at 12 weeks.Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks.At 24 weeks, the fourth cohort experienced the largest average reduction in SDI...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.11.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the t...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.11.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Nov. 7, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the third qu...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.11.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Oct. 31, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce that it has completed a non-brokered pr...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.11.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce that it has completed a non-brok...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.10.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Oct. 28, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting two poster...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.10.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Oct. 28, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting two...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.10.2024       Eupraxia Pharmaceuticals
CA29842P1053

Publication of Eupraxia's Phase 2b data in Lancet Rheumatology, a distinguished and respected journal, raises the profile of EP-104IAR.As outlined in Lancet Rheumatology, Eupraxia's EP-104IAR imparts clinically significant and durable pain relief, while also having minimal changes in glucose and cortisol, along with stable fluticasone proportiona...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.10.2024       Eupraxia Pharmaceuticals
CA29842P1053

Publication of Eupraxia's Phase 2b data in Lancet Rheumatology, a distinguished and respected journal, raises the profile of EP-104IAR.As outlined in Lancet Rheumatology, Eupraxia's EP-104IAR imparts clinically significant and durable pain relief, while also having minimal changes in glucose and cortisol, along with stable fluticasone proportiona...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.10.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Oct. 10, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting a p...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 02.10.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Oct. 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the recent appointments of Chief Scienti...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 02.10.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Oct. 2, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the recent appointments of Chief Scientific Off...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.09.2024       Eupraxia Pharmaceuticals
CA29842P1053

Consistent improvement in patient reported outcomes with 10 of 11 evaluable patients in the first four cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeksThe fourth cohort showed the greatest percentage change in histology (EoEHSS2) scores of any cohort to dateThe RESOLVE Phase 1b/2a trial is progressing as anticipated with no s...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.09.2024       Eupraxia Pharmaceuticals
CA29842P1053

Consistent improvement in patient reported outcomes with 10 of 11 evaluable patients in the first four cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeksThe fourth cohort showed the greatest percentage change in histology (EoEHSS2) scores of any cohort to dateThe RESOLVE Phase 1b/2a trial is progressing as anticipated with no s...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.09.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Sept. 4, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting at...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.09.2024       Eupraxia Pharmaceuticals
CA29842P1053

VICTORIA, BC, Sept. 4, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting at the upc...
Read more
Eupraxia Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink